```html

Gamma‑hydroxybutyrate (GHB) Toxicity – A Patient‑Focused Medical Guide

Overview

Gamma‑hydroxybutyrate (GHB) is a central‑acting depressant that occurs naturally in the human brain in small amounts. When taken in higher doses it produces euphoria, disinhibition, and profound sedation. Because of its intoxicating properties, GHB has been used recreationally and, historically, as a “date‑rape” drug. Toxicity occurs when the dose exceeds an individual’s capacity to metabolize the substance, leading to central nervous system (CNS) depression, respiratory compromise, and metabolic disturbances.

GHB toxicity can affect anyone who ingests the drug—most commonly teenagers and young adults (ages 15‑30) who use it at parties, clubs, or private gatherings. In the United States, the Drug Abuse Warning Network reported ≈ 7,000 emergency department (ED) visits annually for GHB or its analogue γ‑butyrolactone (GBL) between 2016‑2020, a 30 % increase from the prior decade.<sup>[1]</sup> Worldwide, exact prevalence is difficult to determine because many cases are mis‑identified as “alcohol poisoning,” but surveys suggest that 1–2 % of club‑going adolescents have tried GHB at least once.<sup>[2]</sup>

Symptoms

Symptoms of GHB toxicity develop rapidly—usually within 15–30 minutes after ingestion—and can progress from mild to life‑threatening within an hour. The severity depends on dose, purity, concurrent drug/alcohol use, and individual metabolic factors.

Mild‑to‑moderate toxicity

• Euphoria or “high” – feelings of warmth, sociability, and reduced anxiety.
• Dizziness or light‑headedness – a sense of “floating.”
• Nausea / vomiting – common with higher doses.
• Blurred vision – difficulty focusing.
• Headache – often throbbing.
• Impaired coordination – clumsiness, stumbling.
• Slurred speech – similar to alcohol intoxication.

Severe toxicity

• Marked sedation or “coma” – inability to stay awake, unresponsiveness.
• Respiratory depression – slow, shallow breathing (≤ 8 breaths/min) or apnea.
• Bradycardia – heart rate < 60 bpm, sometimes < 40 bpm.
• Hypotension – systolic BP < 90 mmHg, causing dizziness or fainting.
• Hypothermia – body temperature ↓ below 35 °C (95 °F).
• Seizures – less common but reported, especially with mixed‑drug use.
• Vomiting with aspiration – leading to pneumonia.
• Cardiac arrhythmias – rare but serious.

Causes and Risk Factors

What causes GHB toxicity?

GHB toxicity is caused by ingesting a dose that overwhelms hepatic metabolism. The liver converts GHB to carbon dioxide and water via the enzyme succinate‑semialdehyde dehydrogenase. When intake exceeds this pathway’s capacity, plasma GHB levels rise quickly, producing CNS depression.

Common sources

• Recreational powder or liquid sold as “liquid Ecstasy,” “G,” or “date‑rape” drug.
• Gamma‑butyrolactone (GBL) or 1,4‑butanediol (1,4‑BD) – pro‑drugs that convert to GHB in the body.
• Prescription sodium oxybate (Xyrem®) – an FDA‑approved treatment for narcolepsy; misuse or accidental overdose can cause toxicity.

Risk factors

• Age 15‑30 – higher likelihood of experimentation.
• Polydrug use – especially alcohol, benzodiazepines, or opioids, which potentiate CNS depression.
• Low body weight or fasting state – less metabolic reserve.
• Chronic liver disease – reduced clearance.
• History of substance use disorder – increased chance of repeated exposure.

Diagnosis

Diagnosing GHB toxicity is primarily clinical, based on history, observed signs, and exclusion of other causes (e.g., alcohol, benzodiazepines, opioids). Laboratory confirmation is challenging because GHB has a short serum half‑life (< 30 minutes) and rapidly degrades in blood samples.

Key diagnostic steps

• History taking – ask about recent party attendance, known ingestion of “liquid Ecstasy,” or prescription use of sodium oxybate.
• Physical examination – assess airway, breathing, circulation, pupil size, and level of consciousness (Glasgow Coma Scale).
• Point‑of‑care testing – urine drug screens often do NOT detect GHB; specialized liquid‑chromatography mass‑spectrometry (LC‑MS) is needed, but results are usually unavailable in the acute setting.
• Blood glucose – to rule out hypoglycemia, which can mimic GHB’s neurologic picture.
• Arterial blood gas (ABG) – assesses respiratory depression and acidosis.
• Serum electrolytes, BUN/creatinine, liver function tests – evaluate end‑organ impact.

Because definitive testing takes time, emergency physicians treat suspected GHB toxicity empirically based on presentation.

Treatment Options

Management focuses on supportive care, airway protection, and preventing complications. No specific antidote exists.

Immediate emergency interventions

1. Airway, Breathing, Circulation (ABCs) – Ensure a patent airway; consider endotracheal intubation if the patient cannot protect the airway or has a GCS ≤ 8.
2. Supplemental oxygen or mechanical ventilation – for hypoxia or respiratory failure.
3. IV fluid resuscitation – isotonic crystalloids (e.g., 0.9 % saline) to maintain blood pressure.
4. Monitoring – continuous cardiac, pulse‑ox, and end‑tidal CO₂ monitoring.

Pharmacologic measures

• Benzodiazepines (e.g., lorazepam) – May be used for agitation or seizures; they do not reverse GHB depression but can prevent over‑excitation during emergence.
• Flumazenil – NOT indicated, as it can precipitate seizures in mixed overdose.
• Activated charcoal – Considered if the patient presents within 30 minutes of ingestion and the airway is protected; limited benefit due to rapid absorption.

Observation period

Because the half‑life of GHB is short, most patients improve within 4–6 hours after cessation of exposure. However, a 24‑hour observation is recommended for patients with:

• Concurrent alcohol/opioid use
• Significant respiratory depression
• Underlying medical conditions (e.g., liver disease)

Discharge planning

• Ensure the patient is fully awake, with stable vitals, and able to ambulate safely.
• Provide written instructions on signs that require immediate return.
• Arrange referral to addiction services if misuse is suspected.

Living with Gamma‑hydroxybutyrate (GHB) Toxicity

For individuals who have experienced an overdose or who use GHB therapeutically (e.g., sodium oxybate for narcolepsy), ongoing management includes education, monitoring, and lifestyle adjustments.

Self‑monitoring strategies

• Maintain a dosing diary – record exact dosage, time, and any concomitant substances.
• Never mix GHB with alcohol or CNS depressants.
• Stay hydrated – water helps renal clearance, but avoid excessive intake (> 3 L/day) which can lead to hyponatremia.
• Use a trusted “sober buddy” – someone who can call emergency services if you become unconscious.

Medical follow‑up

• Annual evaluation of liver function and renal function if chronic use is present.
• Neuropsychological assessment if you notice memory problems or mood changes after repeated exposures.
• For prescribed sodium oxybate, strict adherence to the FDA‑approved titration schedule and regular sleep‑study follow‑up.

Psychosocial support

Engage in counseling, peer‑support groups (e.g., SMART Recovery, local NA chapters), and, when appropriate, medication‑assisted treatment for co‑occurring substance‑use disorders.

Prevention

• Education – Inform teens, college students, and party organizers about the rapid onset and dangerous synergy of GHB with alcohol.
• Label awareness – Prescription sodium oxybate is only dispensed in a restricted‑distribution program (REMS). Do not share medication.
• Safe environment – If GHB is being used recreationally (which is illegal), ensure a sober monitor, avoid solitary use, and have emergency contact numbers on hand.
• Policy & law enforcement – Support community initiatives that limit illicit GHB distribution.

Complications

If untreated or delayed, GHB toxicity can lead to serious, sometimes irreversible, outcomes.

• Hypoxic brain injury – due to prolonged apnea.
• aspiration pneumonia – from vomiting while unconscious.
• Cardiac arrest – secondary to severe bradycardia or hypotension.
• Rhabdomyolysis – prolonged immobilization can cause muscle breakdown, leading to acute kidney injury.
• Persistent neurocognitive deficits – memory, attention, and executive function impairments reported after repeated high‑dose exposures.

When to Seek Emergency Care

References

1. Centers for Disease Control and Prevention. Drug Abuse Warning Network (DAWN) – Emergency Department Visits, 2016‑2020. https://www.cdc.gov/drugoverdose/data/dawe.html
2. World Health Organization. Global status report on alcohol and drug use 2022. https://www.who.int/publications/i/item/9789240048232
3. Mayo Clinic. Gamma‑hydroxybutyrate (GHB) poisoning. https://www.mayoclinic.org
4. Cleveland Clinic. GHB (Gamma‑hydroxybutyrate) Intoxication. https://my.clevelandclinic.org
5. National Institute on Drug Abuse. GHB Factsheet. https://www.drugabuse.gov
6. American Academy of Emergency Medicine. Clinical Considerations for GHB Overdose. https://www.aaem.org

```